Final results from a phase I trial of ixabepilone in patients with advanced malignancies and lymphoma.

被引：0
|
作者：
Aghajanian, C.
O'Connor, O.
Cohen, M.
Peck, R.
Burris, H.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bristol Myers Squibb Co, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Wallingford, CT USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88S / 88S
页数：1
相关论文
共 50 条
  • [1] Ixabepilone given weekly in patients with advanced malignancies: Final efficacy and safety results of a phase I trial.
    Dickson, N.
    Peck, R.
    Wu, C.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 89S - 89S
  • [2] Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
    Gonzalez-Angulo, Ana M.
    Meric-Bernstam, Funda
    Chawla, Sant
    Falchook, Gerald
    Hong, David
    Akcakanat, Argun
    Chen, Huiqin
    Naing, Aung
    Fu, Siqing
    Wheler, Jennifer
    Moulder, Stacy
    Helgason, Thorunn
    Li, Shaoyi
    Elias, Ileana
    Desai, Neil
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5474 - 5484
  • [3] A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
    Plummer, Ruth
    Woll, Penella
    Fyfe, David
    Boddy, Alan V.
    Griffin, Melanie
    Hewitt, Paula
    Carmichael, James
    Namouni, Fouad
    Cohen, Marvin
    Verrill, Mark
    CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8288 - 8294
  • [4] Phase I study of Ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies
    Tan, Antoinette R.
    Mekhail, Tarek
    Edelman, Martin J.
    Rubin, Eric H.
    Iacono, Lisa C.
    Linowski, Greg
    Trifan, Ovid C.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3578S - 3578S
  • [5] A Phase I Trial of Irinotecan Alternating With Epirubicin in Patients With Advanced Malignancies
    Goff, Laura W.
    Rothenberg, Mace L.
    Lockhart, A. Craig
    Roth, Bruce J.
    VerMeulen, Wendy L.
    Chan, Emily
    Berlin, Jordan D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (05): : 413 - 416
  • [6] Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies.
    Faivre, SJ
    Delbaldo, C
    Pautier, P
    Boige, V
    Henriet, S
    Armand, JP
    Grau, B
    Namouni, F
    Peck, R
    Raymond, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [7] Phase I trial of dasatinib and ixabepilone in patients with solid tumors
    Herbolsheimer, P.
    Kapoor, R.
    Smith, K. L.
    Perry, D.
    Verma, N.
    Veytsman, I.
    Jelinek, J.
    Swain, S. M.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 92 - 98
  • [8] Phase I trial of dasatinib and ixabepilone in patients with solid tumors
    P. Herbolsheimer
    R. Kapoor
    K. L. Smith
    D. Perry
    N. Verma
    I. Veytsman
    J. Jelinek
    S. M. Swain
    Investigational New Drugs, 2013, 31 : 92 - 98
  • [9] Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety profile and maximum tolerated dose
    Tan, A. R.
    Mekhail, T.
    Edelman, M. J.
    Iacono, L. C.
    Messina, M.
    Trifan, O. C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 131 - 131
  • [10] A phase I study of oral ixabepilone in patients with advanced solid tumors
    John F. Deeken
    John L. Marshall
    Michael J. Pishvaian
    Jimmy Hwang
    Christoph M. Ahlers
    Pamela L. Clemens
    Susan M. Parker
    Lisa Iacono
    Patricia M. LoRusso
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1071 - 1078
12345